| A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells CA Vakulskas, DP Dever, GR Rettig, R Turk, AM Jacobi, MA Collingwood, ... Nature medicine 24 (8), 1216-1224, 2018 | 723 | 2018 |
| Tuning the antigen density requirement for CAR T-cell activity RG Majzner, SP Rietberg, E Sotillo, R Dong, VT Vachharajani, ... Cancer discovery 10 (5), 702-723, 2020 | 346 | 2020 |
| Gene correction for SCID-X1 in long-term hematopoietic stem cells M Pavel-Dinu, V Wiebking, BT Dejene, W Srifa, S Mantri, CE Nicolas, ... Nature communications 10 (1), 1634, 2019 | 208 | 2019 |
| Highly efficient and marker-free genome editing of human pluripotent stem cells by CRISPR-Cas9 RNP and AAV6 donor-mediated homologous recombination RM Martin, K Ikeda, MK Cromer, N Uchida, T Nishimura, R Romano, ... Cell stem cell 24 (5), 821-828. e5, 2019 | 161 | 2019 |
| Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans T Thum, K Schmitter, F Fleissner, V Wiebking, B Dietrich, JD Widder, ... European heart journal 32 (10), 1275-1286, 2011 | 64 | 2011 |
| Genome editing of donor-derived T cells to generate allogeneic chimeric antigen receptor-modified T cells: optimizing αβ T-cell-depleted haploidentical hematopoietic stem cell … V Wiebking, CM Lee, N Mostrel, P Lahiri, R Bak, G Bao, MG Roncarolo, ... Haematologica 106 (3), 847, 2021 | 52 | 2021 |
| Metabolic engineering generates a transgene-free safety switch for cell therapy V Wiebking, JO Patterson, R Martin, MK Chanda, CM Lee, W Srifa, G Bao, ... Nature Biotechnology 38 (12), 1441-1450, 2020 | 45 | 2020 |
| T-cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors M Kurzay, F Hauck, I Schmid, V Wiebking, A Eichinger, E Jung, ... Haematologica 104 (10), e478, 2019 | 38 | 2019 |
| Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease V Wiebking, S Hütker, I Schmid, S Immler, T Feuchtinger, MH Albert Annals of hematology 96, 1373-1377, 2017 | 36 | 2017 |
| Maturation of platelet function during murine fetal development in vivo A Margraf, C Nussbaum, I Rohwedder, S Klapproth, ARM Kurz, A Florian, ... Arteriosclerosis, Thrombosis, and Vascular Biology 37 (6), 1076-1086, 2017 | 35 | 2017 |
| MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD AM Boekstegers, F Blaeschke, I Schmid, V Wiebking, S Immler, ... Bone marrow transplantation 52 (8), 1221-1224, 2017 | 21 | 2017 |
| Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702–723 RG Majzner, SP Rietberg, E Sotillo, R Dong, VT Vachharajani, ... | 17 | 2020 |
| Allogeneic stem cell transplantation in adolescents and young adults with primary immunodeficiencies MH Albert, F Hauck, V Wiebking, S Aydin, G Notheis, S Koletzko, M Führer, ... The Journal of Allergy and Clinical Immunology: In Practice 6 (1), 298-301. e2, 2018 | 17 | 2018 |
| Organic nitrates differentially modulate circulating endothelial progenitor cells and endothelial function in patients with symptomatic coronary artery disease T Thum, V Wiebking, G Ertl, J Bauersachs Antioxidants & redox signaling 15 (4), 925-931, 2011 | 16 | 2011 |
| IPEX due to an exon 7 skipping FOXP3 mutation with autoimmune diabetes mellitus cured by selective TReg cell engraftment T Magg, V Wiebking, R Conca, S Krebs, S Arens, I Schmid, C Klein, ... Clinical Immunology 191, 52-58, 2018 | 14 | 2018 |
| Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs): updated results … EL Budde, NL Bartlett, P Giri, SJ Schuster, S Assouline, SS Yoon, K Fay, ... Blood 140 (Supplement 1), 3753-3755, 2022 | 11 | 2022 |
| Subcutaneous (SC) administration of mosunetuzumab with cycle 1 step-up dosing is tolerable and active in patients with relapsed/refractory B-cell non-Hodgkin lymphomas (R/R B … NL Bartlett, P Giri, LE Budde, SJ Schuster, S Assouline, MJ Matasar, ... Blood 138, 3573, 2021 | 8 | 2021 |
| Reengineering ponatinib to minimize cardiovascular toxicity AP Hnatiuk, AAN Bruyneel, D Tailor, M Pandrala, A Dheeraj, W Li, ... Cancer research 82 (15), 2777-2791, 2022 | 7 | 2022 |
| Selection-free, high frequency genome editing by homologous recombination of human pluripotent stem cells using Cas9 RNP and AAV6 RM Martin, K Ikeda, N Uchida, K Cromer, T Nishimura, DP Dever, ... BioRxiv, 252163, 2018 | 7 | 2018 |
| Ambulanzmanual Pädiatrie von AZ I Schmid Springer Berlin Heidelberg, 2012 | 3 | 2012 |
